Unexpected pure red series aplastic anemia secondary to pembrolizumab treatment: a case report and literature review

被引:4
作者
Meri-Abad, Marina [1 ]
Cunquero Tomas, Alberto Jacobo [1 ]
Berrocal Jaime, Alfonso [1 ]
机构
[1] Univ Gen Hosp Valencia, Med Oncol Dept, Valencia, Spain
关键词
aplastic anemia; immunotherapy; melanoma; pembrolizumab; NIVOLUMAB; MELANOMA; IPILIMUMAB;
D O I
10.1097/CMR.0000000000000724
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pembrolizumab is a treatment that has shown a survival benefit in patients with metastatic melanoma. Programmed death receptor 1 inhibitors are new therapeutic agents that produce clinical responses with a more manageable profile of adverse effects compared to chemotherapy. The most frequent adverse effects include fatigue, rash, myalgia, pyrexia and cough, with less frequent occurrence of immune-mediated adverse reactions such as colitis, pneumonitis, hepatitis and encephalitis. Immune-related hematological toxicities have been poorly described. Here we present the case of a patient with metastatic melanoma who develops pure red series aplasia after almost 3 years of treatment with pembrolizumab. To our knowledge, this is the first case of aplastic anemia during treatment with pembrolizumab, with some peculiarities compared to the published cases in the literature.
引用
收藏
页码:186 / 189
页数:4
相关论文
共 17 条
  • [1] Nivolumab-induced aplastic anemia: A case report and literature review
    Comito, Rachel R.
    Badu, Lynette A.
    Forcello, Nicholas
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (01) : 221 - 225
  • [2] Hematologic Complications of Immune Checkpoint Inhibitors
    Davis, Elizabeth J.
    Salem, Joe-Elie
    Young, Arissa
    Green, Jennifer R.
    Ferrell, P. Brent
    Ancell, Kristin K.
    Lebrun-Vignes, Benedicte
    Moslehi, Javid J.
    Johnson, Douglas B.
    [J]. ONCOLOGIST, 2019, 24 (05) : 584 - 588
  • [3] Furie R., 2019, SEMIN ARTHRITIS RHEU, V48, P90
  • [4] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Haanen, J. B. A. G.
    Carbonnel, F.
    Robert, C.
    Kerr, K. M.
    Peters, S.
    Larkin, J.
    Jordan, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 119 - 142
  • [5] Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    Hamid, O.
    Robert, C.
    Daud, A.
    Hodi, F. S.
    Hwu, W. J.
    Kefford, R.
    Wolchok, J. D.
    Hersey, P.
    Joseph, R.
    Weber, J. S.
    Dronca, R.
    Mitchell, T. C.
    Patnaik, A.
    Zarour, H. M.
    Joshua, A. M.
    Zhao, Q.
    Jensen, E.
    Ahsan, S.
    Ibrahim, N.
    Ribas, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (04) : 582 - 588
  • [6] Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma
    Helgadottir, H.
    Kis, L.
    Ljungman, P.
    Larkin, J.
    Kefford, R.
    Ascierto, P. A.
    Hansson, J.
    Masucci, G.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (07) : 1672 - 1673
  • [7] Hollinger MK., 2019, EXP HEMATOL, P17
  • [8] Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin
    Isoda, Atsushi
    Miyazawa, Yuri
    Tahara, Kenichi
    Mihara, Masahiro
    Saito, Akio
    Matsumoto, Morio
    Sawamura, Morio
    [J]. INTERNAL MEDICINE, 2020, 59 (16) : 2041 - 2045
  • [9] Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
    Judd, Julia
    Zibelman, Matthew
    Handorf, Elizabeth
    O'Neill, John
    Ramamurthy, Chethan
    Bentota, Sasini
    Doyle, Jamie
    Uzzo, Robert G.
    Bauman, Jessica
    Borghaei, Hossein
    Plimack, Elizabeth R.
    Mehra, Ranee
    Geynisman, Daniel M.
    [J]. ONCOLOGIST, 2017, 22 (10) : 1232 - 1237
  • [10] Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
    Meyers, D. E.
    Hill, W. F.
    Suo, A.
    Jimenez-Zepeda, V.
    Cheng, T.
    Nixon, N. A.
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7